The group developing the vaccine is also making use of a new vaccine technology, which uses synthetic DNA design to deliver custom vaccines and antigens. Researchers believe that this technology is better suited than any other vaccine technology, and lessens the risk of side-effects, which is one of the biggest problems we can face when a COVID vaccine is used at a public level in the future course of time.
For one, the synthetic vaccine will be able to help the elderly and high-risk, more vulnerable sect of people, which will be a big advantage for them.
“Most research groups have used established approaches to vaccine development because of the urgent need to tackle the pandemic. We all hope the current clinical trials have a positive outcome, but even successful vaccines are likely to have their limitations – they may be unsuitable for vulnerable people, and we do not know how long their effects will last for, for example,” Dr Rebecca Kinsley, Post-Doctoral Researcher and Chief Operating Officer of DIOSynVax mentioned in a briefing.
More News
Number of tests by 2 private labs at Mohalla clinics sees 80% dip since ACB report | India News – Times of India
Adhir Chowdhury Reveals Why Congress Attacks Adani-Ambani; BJP Hits Back
Murder convict gets furlough, victim’s kin move Supreme Court | India News – Times of India